Home / Retatrutide / Side effects
Retatrutide side effects
Phase 3, not approved Retatrutide has no FDA label. Rates below are from Eli Lilly's TRIUMPH-1 phase 3 topline (May 2026, 80 weeks) as reported by the trade press; the peer-reviewed paper confirms stomach and gut effects were most common.
How common each side effect is
| Side effect | Placebo | 4 mg | 9 mg | 12 mg |
|---|---|---|---|---|
| Nausea | 14.8% | 28.6% | 38.4% | 42.4% |
| Diarrhea | 13.5% | 25.2% | 34.1% | 32.0% |
| Constipation | 10.9% | 23.8% | 25.9% | 26.1% |
| Vomiting | 4.8% | 10.6% | 22.8% | 25.3% |
| Dysesthesia (skin sensitivity, burning) | 0.9% | 5.1% | 12.3% | 12.5% |
| Stopped because of side effects | 4.9% | 4.1% | 6.9% | 11.3% |
TRIUMPH-1, adults with obesity and no diabetes. Company topline via trade press; not yet checked against the full paper.
Other numbers worth knowing
| Trial size | 2,339 adults, 80 weeks (TRIUMPH-1) |
| Phase 2 (2023) | Side effects were mainly stomach and gut, dose-related, mostly mild to moderate, and fewer when starting at 2 mg instead of 4 mg |
| Heart rate (phase 2) | Rose with dose, peaked at 24 weeks, then declined |
| Long-term safety | Unknown: there is no label and no post-approval data |
When side effects happen
In phase 2, starting at a lower dose (2 mg) reduced stomach and gut side effects. TRIUMPH-1 started at 2 mg and stepped up every 4 weeks.
Not medical advice. Contact your prescriber about side effects that are severe or do not go away, and get urgent care for severe stomach pain, signs of an allergic reaction or trouble breathing.
More on Retatrutide: dosage and status ·units calculator
Side effects of: Tirzepatide · Semaglutide · BPC-157
Questions
- What are the most common side effects of retatrutide?
- Nausea, diarrhea, constipation and vomiting. In TRIUMPH-1, nausea affected 42.4% at 12 mg vs 14.8% on placebo, according to the company topline.
- Is retatrutide harder to tolerate than tirzepatide?
- They have not been compared head to head. In their own trials, about 11% stopped retatrutide 12 mg because of side effects, vs about 7% on tirzepatide 15 mg; different trials and populations, so treat that as a rough guide only.
- What is retatrutide dysesthesia?
- An abnormal skin sensation such as tingling, burning or sensitivity to touch. It was reported by about 12% at 9 and 12 mg vs 0.9% on placebo. Lilly described it as generally mild to moderate.
- Are retatrutide side effects from research peptide sellers the same?
- Nobody knows. Trial data come from a pharmaceutical-grade product at known doses. Products sold online as 'research' retatrutide are not checked for identity, purity or dose, and the FDA has sent warning letters to sellers.
Sources
- Jastreboff et al. Retatrutide for the treatment of obesity (TRIUMPH-1). NEJM 2026 (PubMed)
- HCPLive: Retatrutide meets weight-loss endpoints in phase 3 obesity trial (Lilly topline, May 2026)
- Jastreboff et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. NEJM 2023
- FDA warning letter to TXP Innovations (Tex Peptides), Aug 24, 2026
Last checked 2026-11-16. How we pick and check sources: methodology.